Airway Epithelium Gene Expression: AEGIS IDE
- Conditions
- Lung Cancer
- Registration Number
- NCT00746759
- Lead Sponsor
- Allegro Diagnostics, Corp.
- Brief Summary
The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.
- Detailed Description
Allegro Diagnostics is funding this multi-center study to validate and extend a new diagnostic tool measuring global gene expression in airway epithelial cells obtained at routine bronchoscopy in suspect lung cancer patients. The test, which is highly sensitive and specific for lung cancer, measures the levels of expression of genes in cells brushed from the large bronchi during diagnostic bronchoscopy. Similar brushings of epithelial cells from the nose will be analyzed to determine if gene expression in these cells can be used as a screening tool in subjects who may have now or be at risk for developing lung cancer in the future.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1331
- Patients being evaluated for the diagnosis of possible lung cancer or "rule out lung cancer" and undergoing clinically indicated bronchoscopy
- All patients are required to be at least 21 years of age and be able to understand and sign the informed consent form
- Patient must be a current or former cigarette smoker
- A pulmonary physician does not recommend that bronchoscopy be performed
- Inability to understand the written consent form and comply with requirements of the study
- History of prior primary lung cancer
- Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator for >24 consecutive hours.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Lung Cancer Diagnosis (positive or negative) 12 months Patients may be followed at 12 months post bronchoscopy to finalize diagnosis if diagnosis had not previously been confirmed. The biomarker score will be compared to the standard diagnosis to evaluate the sensitivity, specificity, and negative predictive values of the biomarker.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (21)
University of Alabama
🇺🇸Birmingham, Alabama, United States
Pulmonary Associates of Arizona
🇺🇸Phoenix, Arizona, United States
University of California- Davis
🇺🇸Sacramento, California, United States
National Jewish Health
🇺🇸Denver, Colorado, United States
Yale Univeristy
🇺🇸New Haven, Connecticut, United States
North Florida/South Georgia VA
🇺🇸Gainesville, Florida, United States
Indiana University
🇺🇸Indianapolis, Indiana, United States
LSU
🇺🇸New Orleans, Louisiana, United States
St. Elizabeth's Medical Center
🇺🇸Boston, Massachusetts, United States
University of Missouri
🇺🇸Columbia, Missouri, United States
Scroll for more (11 remaining)University of Alabama🇺🇸Birmingham, Alabama, United States